Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Summary

The main purpose of this extended study is to enable subjects who are currently receiving the PartB experimental drug in the HR-TPO-ITP-III-PED clinical trial .To continue receiving the experimental drug after the completion of the clinical trial if they benefit from the treatment at the end of the clinical trial.Until the study physician determines that the subject has failed treatment or that the subject can no longer benefit from treatment or extends the study treatment for 6 months.In addition, the secondary purpose of this extended study was to observe the long-term efficacy and safety of tripodal in children and adolescents.

Timeline

Start

2023-01-23

Primary completion

2024-06-30

Completion

2024-06-30

Drugs

Indications